CWM
TXMD icon

Cornerstone Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Cornerstone Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-166
Closed -$1.65M – 1092
2018
Q3 		$1.65M Sell
166
-598
-78% -$183K 0.02% 562
2018
Q2 		$6.02M Buy
+764
New +$233K 0.07% 283

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Cornerstone Wealth Management's TXMD Position: Q4 2018 in Review

Cornerstone Wealth Management sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 166 shares — an estimated $1.65M sold.

Cornerstone Wealth Management first reported a position in TXMD in Q2 2018 and held it in 2 quarters. The position peaked at $6.02M in Q2 2018. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

  • Cornerstone Wealth Management reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
  • Cornerstone Wealth Management sold 166 TherapeuticsMD shares in Q4 2018, an estimated $1.65M.
  • Cornerstone Wealth Management first reported a position in TherapeuticsMD in Q2 2018 and held it in 2 quarters.
  • Cornerstone Wealth Management's TherapeuticsMD position peaked at $6.02M in Q2 2018.
  • 140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Cornerstone Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.